心肺运动测试和HFpEF:诊断和治疗的前景
Francesco Di Spigno1, Valeria Dall'Ospedale1, Luigi Gerra1
1Cardiology Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.
Healthcare (Basel, Switzerland)
|December 11, 2025
概括
心肺运动测试 (CPET) 提供了关于心力衰竭与保留喷射分数 (HFpEF) 的有价值的见解. CPET参数可以指导个性化的管理策略,并改善这种复杂疾病中的患者结果.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一个日益严重的全球健康问题,患病率和死亡率很高.
- 心肺运动测试 (CPET) 对于诊断HFpEF至关重要,特别是在患者中,有不明原因的运动性呼吸障碍.
研究的目的:
- 审查HFpEF中CPET参数的临床相关性和预后价值.
- 探索VO2峰值,氧脉冲和VE/VCO2斜率在评估HFpEF患者中的实用性.
主要方法:
- 这是对当前证据的叙述性回顾.
- 该审查侧重于与HFpEF相关的既定和新兴的CPET参数.
主要成果:
- 峰值VO2已在心力衰竭与减少喷射率 (HFrEF) 中建立了预后价值,但其在HFpEF中的作用不那么明确.
- 氧脉冲和VE/VCO2斜率显示了评估功能能力和预测HFpEF结果的潜力,特别是肺高血压.
结论:
- 来自CPET的变量对于评估HFpEF非常有价值.
- 将CPET整合到临床评估中可以指导个性化管理,并改善HFpEF患者的治疗结果.
关键词:
在CPET中,CPET是CPET.HFpEF HFpEF 的意思是什么意思在 VE/VCO2 斜坡上.进行心肺运动测试.运动不耐受 运动不耐受心力衰竭与保存的喷射分数的心脏衰竭氧气脉冲脉冲的时间氧气吸收的峰值时间预后评估预后评估.通风机的效率是非常高的.更多相关视频
相关概念视频
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Pulmonary Function Tests
711
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
711
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362


